GCP
HEPA

GSA Capital Partners’s Hepion Pharmaceuticals HEPA Stock Holding History

GSA Capital Partners’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21
Closed -$23K – 1572
2021
Q4 		$23K Buy
+21
New +$28.8K ﹤0.01% 1356
2021
Q2 		– Sell
-161
Closed -$296K – 1428
2021
Q1 		$296K Buy
161
+72
+81% +$158K 0.05% 653
2020
Q4 		$195K Buy
+89
New +$231K 0.03% 999

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.59B AUM 21.24% 1-Year Est. Return

GSA Capital Partners's HEPA Position: Q1 2022 in Review

GSA Capital Partners sold out of Hepion Pharmaceuticals (HEPA) in Q1 2022, closing a stake of 21 shares — an estimated $23K sold.

GSA Capital Partners first reported a position in HEPA in Q4 2020 and held it in 3 quarters. The position peaked at $296K in Q1 2021. 31 funds tracked by Wall St. Rank hold HEPA as of Q1 2022.

  • GSA Capital Partners reported no remaining Hepion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 21 Hepion Pharmaceuticals shares in Q1 2022, an estimated $23K.
  • GSA Capital Partners first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • GSA Capital Partners's Hepion Pharmaceuticals position peaked at $296K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.